Circulating angiogenic cells (CAC) participate in cardiac repair. CAC recruitment to the ischaemic heart is mainly induced by the chemokine (C-X-C motif) receptor 4 (CXCR4)/stromal-cell derived factor-1a axis. However, CAC mobilization is only partly prevented by CXCR4 blockade, indicating that other mechanisms are involved. Since the expression of monocyte chemotactic protein 3 (MCP3) is increased in ischaemic hearts, we hypothesized that it may participate in CAC mobilization.
Introduction
Mesenchymal stem cells (MSC) have a great therapeutic potential in a number of disease states such as cardiovascular pathologies. Among other subsets of MSC, circulating angiogenic cells (CAC) participate in cardiac repair after ischaemia through revascularization of ischaemic areas of the myocardium. 1 -4 However, little is known about how CAC are recruited to the injured sites. The recruitment of MSC is a sequential process, involving first their mobilization from the bone marrow through rupture of the chemokine (C -X-C motif) receptor 4 (CXCR4)/stromal-cell derived factor-1a (SDF1a) axis and then their migration to sites of injury through chemotaxis. Whereas the CXCR4/SDF1a axis is known to mediate both steps of this process, it is unclear why blocking CXCR4 only partly prevents MSC migration. 5 Schenk et al. 6 observed that monocyte chemotactic protein 3 (MCP3/CCL7) also regulates MSC migration. The chemokine MCP3 is one of the most broadly active chemoattractants which recognizes three different chemokine (C-C motif) receptors, CCR1, CCR2, and CCR3. MCP3 has a very broad range of target cells, including most of the leucocytes (monocytes, eosinophils, basophils, NK cells, T lymphocytes, and neutrophils). 7 -9 Interestingly, MCP3 expression is increased in rat hearts after ischaemia and participates in the recruitment of CD34+ bone marrow progenitors to the ischaemic myocardium. 10 Moreover, MCP3 orchestrates monocyte mobilization to inflammatory sites. 9 We hypothesized that MCP3 may participate in CAC mobilization. Using both in vitro and in vivo approaches, we demonstrate that MCP3 induces CAC migration and angiogenesis.
Methods

Cell culture
Peripheral blood mononuclear cells (PBMC) were isolated from the venous blood of healthy volunteers through separation on a Ficoll gradient using Leucosep tubes (Greiner, Wemmel, Belgium). The investigation conforms with the principles outlined in the Declaration of Helsinki. Approval has been granted by the national Ethics Committee and an informed consent was obtained from each donor. CAC were obtained from PBMC as described previously. 11, 12 Briefly, 8 × 10 6 PBMC were seeded onto human fibronectin (2.5 mg/cm 2 )-coated six-well plates and cultured in EBM media supplemented with brain bovine extract, human recombinant endothelial growth factor, hydrocortisone, gentamicin, amphotericin B, and 20% foetal calf serum (FCS; Lonza, Verviers, Belgium). After 3 days, non-adherent cells were discarded and adherent cells were cultured another 24 h. CAC were positive for classical CAC markers and were double-positive for endothelial-specific lectin and Dillabelled acetylated low-density lipoproteins. Primary monocytes were purified from PBMC by negative selection using the Monocyte Isolation Kit II (Myltenyi Biotech GmbH, Bergisch Gladbach, Germany) and differentiated to macrophages with macrophage colony-stimulating factor for 7 days prior to treatment with heparan sulfate (HS), hyaluronic acid (HY) or lipopolysaccharide (LPS) for 24 h.
Primary human coronary artery endothelial cells (HCAEC) and human microvascular endothelial cells (HMVEC) were cultured following the manufacturer's recommendations (Lonza). Human cardiac fibroblasts were purchased from TCS CellWorks Ltd (Buckingham, UK). Myofibroblasts were obtained by differentiation of fibroblasts with transforming growth factor-b (10 ng/mL) for 24 h.
Flow cytometry
Cells were harvested in non-enzymatic cell dissociation solution and washed twice in phosphate-buffered saline (PBS, Lonza) supplemented with 1% bovine serum albumin (BSA). Two lakh cells were treated with the appropriate amount of Fc-blocking reagent (Miltenyi, Utrecht, The Netherlands) and stained thereafter with specific antibodies or the corresponding isotype control in 50 mL PBS-1% BSA for 30 min at 48C. If required, cells were fixed using the commercial BD FACS lysis solution according to the manufacturer's instructions. Antibodies used were: mouse monoclonal anti-CCR1 (IgG2b-PE clone 53504, R&D System, Oxon, UK), mouse monoclonal anti-CCR2 (IgG2b-Alexa 647 clone 12G5, BD Biosciences, Erembodegem, Belgium), and mouse monoclonal anti-CCR3 (IgG2a-APC clone 61828, R&D System). Twenty thousand to 40 000 events were acquired on a BD FACSCanto TM flow cytometer and analysed with the FACSDiva TM software (BD Biosciences). Overlays were obtained using FlowJo 7.2.4 software.
Real-time polymerase chain reaction
Total RNA was isolated using TriReagent and the RNeasy mini kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. One microgram of total RNA was reverse transcribed using the Superscript II Reverse Transcriptase (Invitrogen, Merelbeke, Belgium). Polymerase chain reaction (PCR) was performed using the iCycler and the IQ TM SYBR Green Supermix (Bio-Rad, Nazareth, Belgium). PCR primer sequences are available upon request. Expression levels were calculated by the 2 DCt method with b-actin as a housekeeping gene.
Chemotactic assay
Chemotaxis experiments were performed in Costar w Transwell TM permeable supports with polycarbonate 5 mm pore size membranes (VWR, Leuven, BE). All experiments were carried out in antibiotic-free CAC medium with 5% FCS. A cell suspension of 1.8 × 10 6 cells/mL of CAC was generated and 100 mL aliquots were distributed in the upper chambers of the Transwell TM permeable supports (180 000 cells/well) or previously incubated for 30 min at 378C with 10 mg/mL of anti-CCR1 (clone 53504, R&D System) and/or anti-CCR7 (clone 150503, R&D System) neutralizing antibodies. The loaded chambers were then transferred to a 24-well plate containing MCP3 or macrophage inflammatory protein 3b (MIP3b, 0 -100 ng/mL). Recombinant human MCP3 and MIP3b were obtained from Peprotech (London, UK). The level of contaminating endotoxin was ,0.1 ng/mg. In some experiments, recombinant chemokines were replaced by conditioned medium from primary macrophages treated by 100 mg/mL HS for 24 h in the same medium that was used to culture CAC. After 6 h at 378C 5% CO 2 , cell migration was evaluated by lysis and DNA staining of cells that crossed the membrane with the CyQUANT dye (Invitrogen). Fluorescence was measured with the POLARstar OPTIMA (BMG Labtech) using excitation at 480 nm and emission at 520 nm.
Enzyme-linked immunosorbent assay
MCP3 concentrations were measured by the CCL7 Quantikine w Colorimetric Sandwich ELISA (R&D Systems). The detection limit of the assay was 1 pg/mL. MIP3b concentrations were measured by the CCL19/ MIP3b DuoSet w Colorimetric Sandwich ELISA (R&D System). The detection limit of the assay was 4 pg/mL.
Animals
This study was conducted in accordance with the regulations of the Animal Welfare Act of the National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH Publication No. 85-23, revised 1996) and protocols were approved by the Regional Veterinary Department ('Direction Départementale de la Protection des Populations'), agreements RAR1A03516811825 and 54-100. Seventeen adult C57BL6 mice (Charles Rivers Laboratories; 8-to 11-weeks old) were enrolled.
In vivo Matrigel
TM plug assay
Growth Factor-Reduced Matrigel TM (18 -22 mg/mL; 500 mL/mouse) (BD Biosciences) was mixed with 100 ng/mL of MCP3 on ice and was injected subcutaneously into the left and right lower abdominal side of nine mice. Six control animals were injected with 500 mL of Matrigel TM containing 50 mL of vehicle. Twenty units of heparin (Tocris Bioscience, Bristol, UK) per plug were used as an anti-coagulant. Each mouse was thoroughly anaesthetized using gaseous isoflurane (3%) before the injection of Matrigel TM . The effectiveness of anaesthesia was verified with the loss of footpad reflex. To inhibit angiogenesis, mice were injected with neutralizing antibodies against CCR1 (33 mg per mouse, R&D Systems Europe, Oxon Abingdon, UK) or the isotype control Sheep IgG (Abcam, Cambridge, UK) on days 1, 3, and 6. Control animals were injected with NaCl. On day 7, mice were sacrificed by pentobarbital overdose (200 mg/kg). The plugs were dissected from the abdomen and placed in 3.7% formaldehyde/PBS at room temperature for 2 days. The plugs were sectioned at 5 mm, stained with haematoxylin and eosin, and examined under microscope at ×400 magnification. Microvessels visible at least 50 mm from a native tissue edge were considered to be newly created and not part of those pre-existing in native tissue. A microvessel was defined as a ring or cylindrical structure with an internal endothelial cell lining. Branched microvessels were counted as one less than the number of arms (i.e. a y-shaped structure would be counted as two). Quantification of microvessels was performed on each whole slice, using ×100 magnification. Two sections per plug were assessed for histological analysis (at one extremity and in the middle of the sections series). To assess CAC recruitment responsible for the neovascularization, we performed immunohistochemical staining for CD31 (mouse monoclonal IgG1, P2B1, Abcam) on two representative slices of each group. Alexa Fluor w 488-coupled donkey anti-mouse antibody (Jackson ImmunoResearch, UK) was used as a secondary antibody. Images were recorded on a confocal microscope (Zeiss Laser Scanning Microscope LSM 510) with a ×400 magnification using the LSM 510 META software. Nuclear staining was performed using DAPI (blue).
Statistical analysis
Results are expressed as mean + SD. Comparisons between the means of two groups were performed with the t-test for Gaussian data or the Mann-Whitney test for non-Gaussian data. Data normality was assessed with the Shapiro -Wilk test. Comparisons between multiple groups were performed with one-way ANOVA. A pairwise multiple comparison procedure (Holm -Sidak method) was used to isolate groups that differ from each other. All tests were two-tailed. The SigmaPlot v11.0 software was used for statistical analysis.
Results
Chemotactic migration of CAC is induced by MCP3
Transwell experiments were undertaken to evaluate the capacity of CAC to migrate along a gradient of MCP3. As shown in Figure 1 , MCP3 concentration-dependently stimulated the migration of CAC (P ¼ 0.01). The effect was significant for concentrations of MCP3 from 10 ng/mL and was maximal with 25 ng/mL MCP3 (one-fold increase, P ¼ 0.001).
Since the MCP3 protein used in this study was a recombinant protein purified from cultures of Escherichia coli, we verified that the migration was effectively due to MCP3 and not to contaminating endotoxin. The migration of CAC was unaffected by 0.01, 1, and 100 ng/mL LPS (data not shown).
The migration of CAC induced by MCP3 involves CCR1
Using flow cytometry, we observed that among the three known MCP3 receptors, CCR1, but not CCR2 or CCR3, was markedly expressed at the surface of CAC (Figure 2A) . It has to be noted that a very small population of CAC also expressed CCR2, and to a still lesser extent CCR3 (see arrows in Figure 2A) . The relative distribution of MCP3 receptors, as assessed by quantitative PCR, was as follows: CCR1 . CCR2 . CCR3 ( Figure 2B ). Since CCR1 was the predominant receptor (76%), we tested its involvement in the migration of CAC induced by MCP3. As shown in Figure 2C , MCP3 concentrationdependently increased the migration of CAC (P , 0.001), and this effect was abrogated by the pre-treatment of CAC with 10 mg/mL of anti-CCR1 antibodies (P ¼ 0.37). These results show that CCR1 mediates the stimulation of CAC migration by MCP3.
The migration of CAC induced by MCP3 is a paracrine mechanism
Measured by ELISA, MCP3 was barely detectable in the conditioned medium of CAC ( Figure 3A) . In addition, the intracellular expression of MCP3 was undetectable by flow cytometry (data not shown). Therefore, we investigated the production of MCP3 by cardiac and inflammatory cells. Fibroblasts, myofibroblasts, and macrophages-but not vascular endothelial cells-produced MCP3. The secretion of MCP3 by macrophages was more than 10-fold higher than by fibroblasts ( Figure 3A ).
Macrophages produce MCP3 upon activation
Having observed that a concentration of 10 ng/mL MCP3 is necessary to trigger CAC migration ( Figure 1 ) and that conditioned medium from resting macrophages contained only 3.5 ng/mL MCP3 ( Figure 3A) , we concluded that macrophages may have to be activated to produce MCP3 in sufficient quantity to induce CAC migration. Since the toll-like receptor 4 is activated in macrophages during cardiac ischaemia and inflammation, we evaluated the effect of several ligands of this receptor on MCP3 production. We used one ligand of bacterial origin (LPS), and two ligands produced in the injured heart by extracellular matrix breakdown, HS 13 and HY. 14 As shown in Figure 3B , only HS up-regulated MCP3 production (five-fold increase, P ¼ 0.03). After 24 h, conditioned medium from HS-treated macrophages contained on average 20 ng/mL MCP3, a concentration sufficient to stimulate CAC migration.
Conditioned medium from activated macrophages stimulates the migration of CAC
Next, we assessed the migration of CAC in response to conditioned medium from HS-treated macrophages. Macrophages were treated for 24 h with 100 mg/mL HS, and the increase in the MCP3 level in conditioned medium was verified before performing migration assays. As shown in Figure 3C , the migration of CAC was increased upon exposure to conditioned medium from HS-treated macrophages (one-fold increase, P ¼ 0.01). Then, CAC were pre-incubated with 10 mg/mL of anti-CCR1 antibodies before seeding in the Transwell. Only a modest inhibition of CAC migration was observed after CCR1 blockade (218%, P ¼ 0.32; Figure 3C ).
MIP3b is a weak inducer of the migration of CAC
We investigated whether other chemokines could also regulate CAC migration. Of note, SDF1a was undetectable in conditioned control; **P , 0.005 vs. control. The concentration-dependent effect of MCP3 was significant (ANOVA, P ¼ 0.01).
MCP3 is a homing factor for angiogenic cells medium from activated macrophages (data not shown). Using microarrays (data not shown), we found that in addition to CCR1 and CXCR4, the chemokine receptor CCR7 was also expressed by CAC, although to a lower extent than CXCR4 and CCR1. It is known that MIP3b binds to CCR7 and triggers the chemotaxis of haematopoietic progenitor cells. 15 The migration of CAC towards purified MIP3b was enhanced (P ¼ 0.03; Figure 4A ). The effect of MIP3b on cell migration was less important than the effect of MCP3 shown in Figure 1 (140% increase in migration for MIP3b compared with 200% for MCP3) and was achieved at higher concentrations ( Figure 4A ). The effect of MIP3b was blocked by anti-CCR7 antibodies. MIP3b was weakly produced by macrophages and highly up-regulated upon stimulation with HS ( Figure 4B) . However, the highest concentration of MIP3b was still much lower (,0.5 ng/mL) than the concentration of MCP3 obtained after HS treatment (20 ng/mL; Figure 3B ). When conditioned medium from HS-treated macrophages was used in migration assays, only a modest inhibitory effect of anti-CCR7 antibodies was observed. The concomitant administration of anti-CCR1 and anti-CCR7 antibodies did not induce a significant additional or synergistic effect ( Figure 4C ). Taken together, these results suggest that MCP3 is a stronger stimulus of CAC migration than MIP3b.
MCP3 induces angiogenesis
We used the Matrigel TM plug assay to test whether MCP3 stimulates CAC recruitment in vivo and is able to induce angiogenesis. Mice were subcutaneously implanted with 500 mL of Matrigel TM containing 100 ng/mL MCP3 or vehicle. To assess the implication of CCR1, mice received three injections of anti-CCR1 antibodies (33 mg/ mouse) or isotype control. After 1 week, mice were sacrificed and plug sections were analysed. In plugs containing MCP3, we observed a significant increase in the development of microvessels ( Figure 5A) . Counting of microvessels revealed a 1.5-fold increase in the microvessel number (P , 0.001). The neutralization of CCR1 severely inhibited microvessel formation induced by MCP3. Microvessels were positive for the endothelial marker CD31, confirming their vascular phenotype ( Figure 5B ). These results demonstrate that MCP3 stimulates angiogenesis in vivo through the activation of CCR1.
Discussion
In this study, we have demonstrated that MCP3 stimulates the migration of CAC, thereby inducing angiogenesis. This observation may have important implications when considering cell therapy for the ischaemic heart. 
MCP3 is a homing factor for angiogenic cells
We observed that CAC did not produce MCP3, indicating that the stimulation of their migration by this chemokine may be a paracrine mechanism. It has been shown in rats that the transplantation of cardiac fibroblasts overexpressing MCP3 into the heart after myocardial infarction recruited MSC to injured tissue and improved cardiac healing. 6 We observed a low but detectable production of MCP3 by fibroblasts and myofibroblasts, indicating that these cells may contribute to the mobilization of CAC upon injury. However, macrophages produced the largest quantity of MCP3 and are therefore thought to be potent triggers of CAC recruitment. It is known that the mobilization of CAC to ischaemic tissues is controlled by the SDF1a/CXCR4 ligand/receptor couple. 16 -18 Here, we show for the first time that the migration of CAC can also be triggered by MCP3. This finding provides an explanation why CXCR4 blockade only partly prevents stem cell migration. 5 This could also be due to a lack of specificity of the antibodies used to neutralize CXCR4. Indeed, the reliability of G-protein-coupled receptor antibodies has been questioned. 19 Similarly, a poor specificity of the anti-CCR1 used in our study may account for the partial inhibition of CAC migration observed after CCR1 blockade ( Figure 3C ). This is however unlikely since the antibody used in these experiments, which was generated by Coughlan et al., 20 recognizes the CCR1 receptor but not the CCR3 receptor, the most closely phylogenetically related chemokine receptor. The specificity of this antibody has also been demonstrated elsewhere.
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A more likely explanation for the partial inhibition of migration by anti-CCR1 may be the presence of other chemokines in conditioned medium from HS-treated macrophages. In our experiments, SDF1a was undetectable in conditioned medium, ruling out a possible role for this chemokine. The MIP3b/CCR7 axis triggers the chemotaxis of hematopoietic progenitor cells. 15 We observed that MIP3b stimulated CAC migration through the CCR7 receptor. This effect was weaker than MCP3, conferring to this latter chemokine the stronger ability to induce the migration of CAC. The dual blockade of CCR1 and CCR7 did not fully block the migration of CAC, suggesting that other chemokines may be involved. Upon activation, macrophages produce interleukin (IL)-6, 22 and IL-6 has been shown to regulate the migration of endothelial progenitor cells through the CD126 receptor. 23 Fractalkine (CX3CL1) may also stimulate CAC migration, since it is involved in macrophage chemotaxis during inflammation 24 and its receptor, CX3CR1, is expressed on endothelial progenitor cells. 25 Overall, the migration of CAC is a complex mechanism implicating multiple chemokines. We identified here MCP3 as an important player.
The efficacy of cell therapy is often limited by a low homing of injected cells to the ischaemic heart. 26 From our results, it can be speculated that MCP3 may be studied as an adjunct to cell therapy to improve the homing to the site of injury.
In conclusion, we have identified MCP3 as a new target to improve cardiac repair. This observation suggests testing concomitant administration of CAC and MCP3 in pre-clinical models of ischaemic cardiac disease.
